Press Releases Aug 8, 2017 • 6:05 AM EDT Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 Aug 3, 2017 • 8:05 AM EDT Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference Aug 1, 2017 • 8:30 AM EDT Matinas BioPharma to Host Quarterly Update Conference Call Jun 26, 2017 • 6:05 AM EDT Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis Jun 3, 2017 • 4:00 PM EDT Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis Jun 2, 2017 • 4:01 PM EDT Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis Jun 1, 2017 • 7:05 AM EDT Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference May 30, 2017 • 8:05 AM EDT Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference May 16, 2017 • 7:05 AM EDT Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update Apr 24, 2017 • 7:00 AM EDT Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases << Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ...15 | Next >>
